Results 241 to 250 of about 49,455 (313)

A study protocol for a systematic review and meta-analysis on macroscopic body movements as a marker for acute stress. [PDF]

Syst Rev
Kurz M, Ringgold V, Abel L, Burkhardt F, Richer R, Schindler-Gmelch L, Turner AI, Eskofier BM, Rohleder N.   +8 more
europepmc   +1 more source

Enhancing security and usability with context aware multi-biometric fusion for continuous user authentication. [PDF]

Sci Rep
S A, K JS.
europepmc   +1 more source

Randomised Controlled Multicentre Trial to Investigate the Effectiveness of a Mobile Artificial Intelligence Solution for Diabetes Adapted Care: The MELISSA Trial Protocol

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Achieving optimal glycaemic control remains a burden for many people with diabetes on intensive insulin treatment. The MELISSA trial aims to clinically validate the artificial intelligence (AI)‐based MELISSA system to support people with Type 1 diabetes on multiple daily insulin injections (MDI) with personalised insulin dose ...
Elisabeth J. den Brok, Cecilie H. Svensson, Mikkel T. Olsen, Nefeli M. Dimitropoulou, Sander M. J. van Kuijk, Maria Panagiotou, Lubnaa Abdur Rahman, Stephan Proennecke, Peter R. Mertens, Stavros Athanasopoulos, Cassy F. Dingena, Konstantinos Makrilakis, Stavroula Mougiakakou, Ulrik Pedersen‐Bjergaard, Bastiaan E. de Galan, on behalf of the MELISSA consortium   +15 more
wiley   +1 more source

PPG-basis: A python-based toolbox for fast photoplethysmogram decomposition and reconstruction. [PDF]

Comput Methods Programs Biomed
Putcha A, Keyal R, Piasecki L, Sharma A, Shmuylovich L, Lou Y, Kosorok M, Bai W.   +7 more
europepmc   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Biometric Technologies [PDF]

, 2018
openaire   +2 more sources

MIMIC-III-Ext-PPG, a PPG-based Benchmark Dataset for Cardiovascular and Respiratory Signal Analysis. [PDF]

Sci Data
Moulaeifard M, Kutscher M, Aston PJ, Charlton PH, Strodthoff N.   +4 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Multiple biometric authentication for online banking system based on multiple fuzzy approach. [PDF]

Sci Rep
Anwar NM, Ahmad SSS, Kausar N, Stević Ž, Gaba YU.   +4 more
europepmc   +1 more source